

Cover Story
By Matthew Bin Han Ong
After an examination of the causes of an avalanche of grant applications directed at NCI, institute officials found that new applications largely come from principal investigators who are switching their research focus to cancer. No other NIH institute or center faces such pressure.
In Brief
Funding Opportunities
Clinical Roundup


Drugs & Targets


NCI Trials


NCI Trials for December 2019
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
Trending Stories
- Class action complaint alleging GRAIL insider fraud resubmitted after dismissal
- Cancer centers adapt to life without site visits as NIH changes CCSG review
- How GLP-1RA drugs are reshaping patient physiology and the future of oncology
- Friends publishes three white papers ahead of annual meeting
Topics: Clinical trials on rare cancers, combination drug trials, multi-regional studies - Jonathan Licht named president, chief scientific officer at Van Andel Institute
- Revolution Medicines’ pancreatic cancer drug received a new priority voucher from FDA















